Arvinas Q3 revenue drops sharply on lower milestone payments

Overview

• US biotech firm's Q3 revenue fell sharply yr/yr due to lower milestone and collaboration payments

• Company posted a wider net loss in Q3 2026 compared to prior year

• Operating expenses declined, mainly from lower R&D and G&A costs

Outlook

• Company expects cash reserves to fund operations into the second half of 2028

Result Drivers

• REVENUE DECLINE - Co attributed lower Q3 revenue to absence of milestone and collaboration payments recognized in prior year

• LOWER R&D COSTS - Q3 R&D expenses fell mainly due to reduced spending on vepdegestrant (ARV-471) program and lower personnel costs

• REDUCED G&A EXPENSES - Co reported lower G&A costs due to reduced personnel, infrastructure, and commercial operations spending

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Arvinas, Inc. is $14.00, about 86.2% above its November 2 closing price of $7.52

Reuters Recommended Reads

• Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

• Nov 2 - Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially

• Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)